Cendakimab
Based on 1 publication(s) in Google Scholar
Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC50s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis).
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.96%
- CAS. Nr.: 2151032-62-9
- Molecular Weight:146.44 kDa
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-P99053
TralokinumabIL-13 Inhibitor -
HY-P99025
LebrikizumabIL-13 Inhibitor -
HY-P99801
PascolizumabAnti-IL-4 Monoclonal Antibody -
HY-P99417
AbrezekimabAnti-Human-IL-13 Antibody Fragment -
HY-P99366A
Tezepelumab (anti-TSLP)Anti-TSLP Antibody -
HY-P9909
Ustekinumab -
HY-P99248
RisankizumabIL-23 IgG Monoclonal Antibody -
HY-P9927
SecukinumabIL-17A Antagonist -
HY-108810
CanakinumabAnti-IL-1β Monoclonal Antibody -
HY-P9931
GuselkumabIL-23 Neutralizing Antibody -
HY-P9956
SiltuximabAnti-IL-6 mAb -
HY-P99909
ElranatamabAnti-CD3E/TNFRSF17 Antibody
Publications Citing Use of MedChemExpress (MCE) Cendakimab
More
Biologische Aktivität
Beschreibung
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
[1]|
IL-13 |
In Vitro
Cendakimab (RPC4046; ABT 308; CC-93538) fully neutralizes IL-13-induced thymus and activation-regulated chemokine from lung epithelial A-549 cells with potencies ranging from 80 to 513 pM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Anwendung
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Human IL-13 Protein can bind Cendakimab. The EC50 for this effect is 21.70 ng/mL.
Chemical Information
-
CAS. Nr. 2151032-62-9
-
Appearance Liquid
-
Molecular Weight 146.44 kDa
-
Color Colorless to light yellow
-
SMILES
[Cendakimab]
-
Synonyms
RPC 4046; ABT 308; CC-93538
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Oral Dis
Stretched Vascular Endothelial Cells Polarized Neutrophils to N2 Type via TRPC1-IL13-STAT3 Axis. [Abstract]2025 Mar;31(3):918-927. PMID: 39462789
Reinheit & Dokumentation
-
Data Sheet (258 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Cendakimab Related Classifications
HY-P99496 Related Classifications
Powered by Bioz